Genetic Signatures Limited
ASX: GSS
Strong respiratory demand lifts revenue but rising losses and an overbought RSI hint at short-term downside risk.
(Source: TradingView) 3-Month Performance Profile of GSS on a DTF compared to S&P/ASX 200 (XJO).
Genetic Signatures reported a net loss of $20.10 million in FY25, widening by 12.55% year-over-year, while operating cash outflow rose 21.4%, refle
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
